MedTrace Logo

Effect of Smoking Cessation on Tuberculosis Treatment Outcomes

NCT04848246 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2021-04-19

No results posted yet for this study

Summary

This study was a Randomized Controlled Trial conducted at Ojha Institute of Chest Diseases, Dow University of Health Sciences, Karachi, among pulmonary tuberculosis patients

Conditions

  • Tuberculosis, Pulmonary

Interventions

DRUG

Bupropion

This group received Bupropion 150 mg twice daily for 10 weeks

BEHAVIORAL

Behavioural Change Communication

This group will receive Behavioural Change Communication

Sponsors & Collaborators

  • Dow University of Health Sciences

    lead OTHER

Principal Investigators

  • Muhammad Tahir Rizwan Khan, M.Phil. · Dow University of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-06
Primary Completion
2019-09-30
Completion
2019-10-15

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04848246 on ClinicalTrials.gov